Bespin Subsidiary, LLC /
Landos Biopharma, Inc.
Landos Biopharma to Become a Subsidiary of Bespin Subsidiary
What happened
Bespin Subsidiary, LLC agreed to acquire Landos Biopharma, Inc. under a merger agreement signed on March 24, 2024. Landos Biopharma will survive the merger as a wholly owned subsidiary of Bespin Subsidiary.
Stockholders are to receive $20.42 in cash per share and a contingent value right that may provide an additional $11.14 in cash if a specified clinical milestone is achieved. Terms weren't disclosed.
The source
Everything on this page comes from the source below.
Landos Biopharma to Become a Subsidiary of Bespin Subsidiary
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Agreement signed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly